Teva Pharmaceutical Industries Ltd. reported third-quarter 2026 non-GAAP earnings of $0.86 per share, above analyst expectations of $0.72 per share.
Revenue was $4.4 billion, compared with consensus estimates of $4.22 billion. Growth in the company’s key innovative brands—Austedo, Ajovy, and Uzedy—reached 33%.
Teva raised its full-year 2026 revenue guidance for Austedo to $2.55 billion-$2.65 billion. It increased guidance for Ajovy to $930 million-$960 million and for Uzedy to $290 million-$310 million.
Separately, Teva agreed with Samsung Bioepis to commercialize two FDA-approved immunology biosimilars in the U.S. The agreement supports Teva’s generics and biosimilars portfolio under its Pivot to Growth strategy.
Teva shares traded higher in premarket trading after the results and guidance update.